News|Articles|October 1, 2002

Xendos study: Orlistat plus diet prevents, delays diabetes onset in obese patients

Orlistat (Xenical) in combination with diet and lifestyle changes significantly prevents obese patients from developing type 2 diabetes, say researchers involved in this 4-year study presented at the 9th International Congress on Obesity, Sao Paulo, Brazil. They add that this is the first time a weight loss drug has been shown to prevent or delay the onset of type 2 diabetes in an at-risk population.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME